Skip to main content
Download PDF

Recent applications and strategies in nanotechnology for lung diseases

Nano Research volume 14, pages 2067–2089 (2021)Cite this article

Abstract

Lung diseases, including COVID-19 and lung cancers, is a huge threat to human health. However, for the treatment and diagnosis of various lung diseases, such as pneumonia, asthma, cancer, and pulmonary tuberculosis, are becoming increasingly challenging. Currently, several types of treatments and/or diagnostic methods are used to treat lung diseases; however, the occurrence of adverse reactions to chemotherapy, drug-resistant bacteria, side effects that can be significantly toxic, and poor drug delivery necessitates the development of more promising treatments. Nanotechnology, as an emerging technology, has been extensively studied in medicine. Several studies have shown that nano-delivery systems can significantly enhance the targeting of drug delivery. When compared to traditional delivery methods, several nanoparticle delivery strategies are used to improve the detection methods and drug treatment efficacy. Transporting nanoparticles to the lungs, loading appropriate therapeutic drugs, and the incorporation of intelligent functions to overcome various lung barriers have broad prospects as they can aid in locating target tissues and can enhance the therapeutic effect while minimizing systemic side effects. In addition, as a new and highly contagious respiratory infection disease, COVID-19 is spreading worldwide. However, there is no specific drug for COVID-19. Clinical trials are being conducted in several countries to develop antiviral drugs or vaccines. In recent years, nanotechnology has provided a feasible platform for improving the diagnosis and treatment of diseases, nanotechnology-based strategies may have broad prospects in the diagnosis and treatment of COVID-19. This article reviews the latest developments in nanotechnology drug delivery strategies in the lungs in recent years and studies the clinical application value of nanomedicine in the drug delivery strategy pertaining to the lung.

References

  1. Azarmi, S.; Roa, W. H.; Löbenberg, R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev. 2008, 60, 863–875.

    CAS  Google Scholar 

  2. Newman, S. P. Drug delivery to the lungs: Challenges and opportunities. Ther. Deliv. 2017, 8, 647–661.

    CAS  Google Scholar 

  3. Patton, J. S.; Brain, J. D.; Davies, L. A.; Fiegel, J.; Gumbleton, M.; Kim, K. J.; Sakagami, M.; Vanbever, R.; Ehrhardt, C. The particle has landed—characterizing the fate of inhaled pharmaceuticals. J. Aerosol. Med. Pulm. Drug Deliv. 2010, 23 Suppl 2, S71–S87.

    Google Scholar 

  4. Yu, C. P. Exact analysis of aerosol deposition during steady breathing. Powder Technol. 1978, 27, 55–62.

    Google Scholar 

  5. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R. L.; Torre, L. A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424.

    Google Scholar 

  6. di Sant’Agnese, P. A.; Davis, P. B. Research in cystic fibrosis (third of three parts). N. Engl. J. Med. 1976, 295, 597–602.

    Google Scholar 

  7. Siafakas, N. M.; Vermeire, P.; Pride, N. B.; Paoletti, P.; Gibson, J.; Howard, P.; Yernault, J. C.; Decramer, M.; Higenbottam, T.; Postma, D. S. et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European respiratory society task force. Eur. Respir. J. 1995, 8, 1398–1420.

    CAS  Google Scholar 

  8. Sevinç, F.; Prins, J. M.; Koopmans, R. P.; Langendijk, P. N. J.; Bossuyt, P. M.; Dankert, J.; Speelman, P. Early switch from intravenous to oral antibiotics: Guidelines and implementation in a large teaching hospital. J. Antimicrob. Chemoth. 1999, 43, 601–606.

    Google Scholar 

  9. MacGregor, R. R.; Graziani, A. L. Oral administration of antibiotics: A rational alternative to the parenteral route. Clin. Infect. Dis. 1997, 24, 457–467.

    CAS  Google Scholar 

  10. Patton, J. S.; Byron, P. R. Inhaling medicines: Delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 2007, 6, 67–74.

    CAS  Google Scholar 

  11. Rosen, H.; Abribat, T. The rise and rise of drug delivery. Nat. Rev. Drug Discov. 2005, 4, 381–385.

    CAS  Google Scholar 

  12. Di Marco, M.; Shamsuddin, S.; Razak, K. A.; Aziz, A. A.; Devaux, C.; Borghi, E.; Levy, L.; Sadun, C. Overview of the main methods used to combine proteins with nanosystems: Absorption, bioconjugation, and encapsulation. Int. J. Nanomedicine 2010, 5, 37–49.

    CAS  Google Scholar 

  13. Roger, E.; Lagarce, F.; Garcion, E.; Benoit, J. P. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine 2010, 5, 287–306.

    CAS  Google Scholar 

  14. Chao, P. Y.; Deshmukh, M.; Kutscher, H. L.; Gao, D. Y.; Rajan, S. S.; Hu, P. D.; Laskin, D. L.; Stein, S.; Sinko, P. J. Pulmonary targeting microparticulate camptothecin delivery system: Anticancer evaluation in a rat orthotopic lung cancer model. Anti-Cancer Drugs 2010, 27, 65–76.

    Google Scholar 

  15. Patton, J. S.; Fishburn, C. S.; Weers, J. G. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc. 2004, 1, 338–344.

    CAS  Google Scholar 

  16. Sung, J. C.; Pulliam, B. L.; Edwards, D. A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007, 25, 563–570.

    CAS  Google Scholar 

  17. Dailey, L. A.; Schmehl, T.; Gessler, T.; Wittmar, M.; Grimminger, F.; Seeger, W.; Kissel, T. Nebulization of biodegradable nanoparticles: Impact of nebulizer technology and nanoparticle characteristics on aerosol features. J. Controlled Release 2003, 86, 131–144.

    CAS  Google Scholar 

  18. Geller, D. E.; Pitlick, W. H.; Nardella, P. A.; Tracewell, W. G.; Ramsey, B. W. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002, 122, 219–226.

    CAS  Google Scholar 

  19. Flume, P. A.; VanDevanter, D. R. Clinical applications of pulmonary delivery of antibiotics. Adv. Drug Deliv. Rev. 2015, 85, 1–6.

    CAS  Google Scholar 

  20. Wenzler, E.; Fraidenburg, D. R.; Scardina, T.; Danziger, L. H. Inhaled antibiotics for gram-negative respiratory infections. Clin. Microbiol. Rev. 2016, 29, 581–632.

    Google Scholar 

  21. Langton Hewer, S. C.; Smyth, A. R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database. Syst. Rev. 2017, 4, CD004197.

    Google Scholar 

  22. Cohen-Cymberknoh, M.; Shoseyov, D.; Kerem, E. Managing cystic fibrosis: Strategies that increase life expectancy and improve quality of life. Am. J. Respir. Crit. Care Med. 2011, 183, 1463–1471.

    Google Scholar 

  23. Mei, L.; Zhu, G. Z.; Qiu, L. P.; Wu, C. C.; Chen, H. P.; Liang, H.; Cansiz, S.; Lv, Y. F.; Zhang, X. B.; Tan, W. H. Self-assembled multifunctional DNA nanoflowers for the circumvention of multidrug resistance in targeted anticancer drug delivery. Nano Res. 2015, 8, 3447–3460.

    CAS  Google Scholar 

  24. Zhou, Q.; Leung, S. S. Y.; Tang, P.; Parumasivam, T.; Loh, Z. H.; Chan, H. K. Inhaled formulations and pulmonary drug delivery systems for respiratory infections. Adv. Drug Deliv. Rev. 2015, 85, 83–99.

    CAS  Google Scholar 

  25. Pérez, B. F.; Méndez, G. A.; Lagos, R. A.; Vargas, M. S. L. Mucociliary clearance system in lung defense. Rev. Med. Chil. 2014, 142, 606–615.

    Google Scholar 

  26. Hardy, C. L.; LeMasurier, J. S.; Mohamud, R.; Yao, J.; Xiang, S. D.; Rolland, J. M.; O’Hehir, R. E.; Plebanski, M. Differential uptake of nanoparticles and microparticles by pulmonary APC subsets induces discrete immunological imprints. J. Immunol. 2013, 191, 5278–5290.

    CAS  Google Scholar 

  27. d’Angelo, I.; Conte, C.; La Rotonda, M. I.; Miro, A.; Quaglia, F.; Ungaro, F. Improving the efficacy of inhaled drugs in cystic fibrosis: Challenges and emerging drug delivery strategies. Adv. Drug Deliv. Rev. 2014, 75, 92–111.

    Google Scholar 

  28. Hoffmann, I. M.; Rubin, B. K.; Iskandar, S. S.; Schechter, M. S.; Nagaraj, S. K.; Bitzan, M. M. Acute renal failure in cystic fibrosis: Association with inhaled tobramycin therapy. Pediatr. Pulm. 2002, 34, 375–377.

    Google Scholar 

  29. Tolker-Nielsen, T. Pseudomonas aeruginosa biofilm infections: From molecular biofilm biology to new treatment possibilities. APMIS 2014, 122, 1–51.

    CAS  Google Scholar 

  30. Allen, T. M.; Cullis, P. R. Drug delivery systems: Entering the mainstream. Science 2004, 303, 1818–1822.

    CAS  Google Scholar 

  31. Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J.; Andries, K. The challenge of new drug discovery for tuberculosis. Nature 2011, 469, 483–490.

    CAS  Google Scholar 

  32. Raeburn, D.; Underwood, S. L.; Villamil, M. E. Techniques for drug delivery to the airways, and the assessment of lung function in animal models. J. Pharmacol. Toxicol. Methods 1992, 27, 143–159.

    CAS  Google Scholar 

  33. Thompson, D. C. J. D. Pharmacology of therapeutic aerosols. Science 1992, 54, 29–59.

    CAS  Google Scholar 

  34. Courrier, H. M.; Butz, N.; Vandamme, T. F. Pulmonary drug delivery systems: Recent developments and prospects. Crit. Rev. Ther. Drug Carrier Syst. 2002, 19, 425–498.

    CAS  Google Scholar 

  35. Clark, A. J. D. D. S. Sciences formulation of proteins and peptides for inhalation. Science 2002, 2, 73–77.

    Google Scholar 

  36. Gill, S.; Löbenberg, R.; Ku, T.; Azarmi, S.; Roa, W.; Prenner, E. J. Nanoparticles: Characteristics, mechanisms of action, and toxicity in pulmonary drug delivery—a review. J. Biomed. Nanotechnol. 2007, 3, 107–119.

    CAS  Google Scholar 

  37. Ranney, D. F. Drug targeting to the lungs. Biochem. Pharmacol. 1986, 35, 1063–1069.

    CAS  Google Scholar 

  38. Barnes, P. J. Nocturnal asthma: Mechanisms and treatment. Br. Med. J. 1984, 288, 1397–1398.

    CAS  Google Scholar 

  39. Surendrakumar, K.; Martyn, G. P.; Hodgers, E. C. M.; Jansen, M.; Blair, J. A. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J. Control. Release 2003, 91, 385–394.

    CAS  Google Scholar 

  40. Cook, R. O.; Pannu, R. K.; Kellaway, I. W. Novel sustained release microspheres for pulmonary drug delivery. J. Control. Release 2005, 104, 79–90.

    CAS  Google Scholar 

  41. Hardy, J. G.; Chadwick, T. S. Sustained release drug delivery to the lungs: An option for the future. Clin. Pharmacokinet. 2000, 39, 1–4.

    CAS  Google Scholar 

  42. Zeng, X. M.; Martin, G. P.; Marriott, C. The controlled delivery of drugs to the lung. Int. J. Pharm. 1995, 124, 149–164.

    CAS  Google Scholar 

  43. Bourzac, K. Nanotechnology: Carrying drugs. Nature 2012, 491, S58–S60.

    Google Scholar 

  44. Pelaz, B.; Alexiou, C.; Alvarez-Puebla, R. A.; Alves, F.; Andrews, A. M.; Ashraf, S.; Balogh, L. P.; Ballerini, L.; Bestetti, A.; Brendel, C. et al. Diverse applications of nanomedicine. ACS Nano 2017, 11, 2313–2381.

    CAS  Google Scholar 

  45. Vij, N. Nano-based rescue of dysfunctional autophagy in chronic obstructive lung diseases. Expert Opin. Drug Deliv. 2017, 14, 483–489.

    CAS  Google Scholar 

  46. Zhong, W.; Zhang, X.; Zhao, M.; Wu, J.; Lin, D. Advancements in nanotechnology for the diagnosis and treatment of multiple myeloma. Biomater. Sci. 2020, 8, 4692–4711.

    CAS  Google Scholar 

  47. Chen, G. Y.; Roy, I.; Yang, C. H.; Prasad, P. N. Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chem. Rev. 2016, 116, 2826–2885.

    CAS  Google Scholar 

  48. Singh, A. P.; Biswas, A.; Shukla, A.; Maiti, P. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. Signal Transduct. Target. Ther. 2019, 4, 33.

    Google Scholar 

  49. Xu, C. C.; Li, H.; Zhang, K. M.; Binzel, D. W.; Yin, H. R.; Chiu, W.; Guo, P. X. Photo-controlled release of paclitaxel and model drugs from RNA pyramids. Nano Res. 2019, 12, 41–48.

    CAS  Google Scholar 

  50. Ma, Q. L.; Fan, Q.; Xu, J. L.; Bai, J. Y.; Han, X.; Dong, Z. L.; Zhou, X. Z.; Liu, Z.; Gu, Z.; Wang, C. Calming cytokine storm in pneumonia by targeted delivery of TPCA-1 using platelet-derived extracellular vesicles. Matter 2020, 3, 287–301.

    Google Scholar 

  51. Zhang, X. Y.; Zhao, M. Y.; Cao, N.; Qin, W.; Zhao, M.; Wu, J.; Lin, D. J. Construction of a tumor microenvironment pH-responsive cleavable PEGylated hyaluronic acid nano-drug delivery system for colorectal cancer treatment. Biomater. Sci. 2020, 8, 1885–1896.

    CAS  Google Scholar 

  52. Wagner, V.; Dullaart, A.; Bock, A. K.; Zweck, A. The emerging nanomedicine landscape. Nat. Biotechnol. 2006, 24, 1211–1217.

    CAS  Google Scholar 

  53. Stella, V. J.; Nti-Addae, K. W. Prodrug strategies to overcome poor water solubility. Adv. Drug Deliv. Rev. 2007, 59, 677–694.

    CAS  Google Scholar 

  54. Savjani, K. T.; Gajjar, A. K.; Savjani, J. K. Drug solubility: Importance and enhancement techniques. Int. Scholar. Res. Not. 2012, 2012, 195727.

    Google Scholar 

  55. De Jong, W. H.; Borm, P. J. A. Drug delivery and nanoparticles: Applications and hazards. Int. J. Nanomedicine 2008, 3, 133–149.

    CAS  Google Scholar 

  56. Zhang, L.; Pornpattananangkul, D.; Hu, C. M. J.; Huang, C. M. Development of nanoparticles for antimicrobial drug delivery. Curr. Med. Chem. 2010, 17, 585–594.

    CAS  Google Scholar 

  57. Murgia, X.; Loretz, B.; Hartwig, O.; Hittinger, M.; Lehr, C. M. The role of mucus on drug transport and its potential to affect therapeutic outcomes. Adv. Drug Deliv. Rev. 2018, 124, 82–97.

    CAS  Google Scholar 

  58. Murgia, X.; Pawelzyk, P.; Schaefer, U. F.; Wagner, C.; Willenbacher, N.; Lehr, C. M. Size-limited penetration of nanoparticles into porcine respiratory mucus after aerosol deposition. Biomacromolecules 2016, 17, 1536–1542.

    CAS  Google Scholar 

  59. Ho, D. K.; Costa, A.; De Rossi, C.; de Souza Carvalho-Wodarz, C.; Loretz, B.; Lehr, C. M. Polysaccharide submicrocarrier for improved pulmonary delivery of poorly soluble anti-infective ciprofloxacin: Preparation, characterization, and influence of size on cellular uptake. Mol. Pharmaceutics 2018, 15, 1081–1096.

    CAS  Google Scholar 

  60. Markman, J. L.; Rekechenetskiy, A.; Holler, E.; Ljubimova, J. Y. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv. Drug Deliv. Rev. 2013, 65, 1866–1879.

    CAS  Google Scholar 

  61. Zhu, X.; Radovic-Moreno, A. F.; Wu, J.; Langer, R.; Shi, J. J. Nanomedicine in the management of microbial infection —overview and perspectives. Nano Today 2014, 9, 478–498.

    CAS  Google Scholar 

  62. Abed, N.; Couvreur, P. Nanocarriers for antibiotics: A promising solution to treat intracellular bacterial infections. Int. J. Antimicrob. Agents 2014, 43, 485–496.

    CAS  Google Scholar 

  63. Champion, J. A.; Katare, Y. K.; Mitragotri, S. Particle shape: A new design parameter for micro- and nanoscale drug delivery carriers. J. Controlled Release 2007, 121, 3–9.

    CAS  Google Scholar 

  64. Gao, W. W.; Thamphiwatana, S.; Angsantikul, P.; Zhang, L. F. Nanoparticle approaches against bacterial infections. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2014, 6, 532–547.

    CAS  Google Scholar 

  65. Siegel, R. L.; Miller, K. D.; Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 2019, 69, 7–34.

    Google Scholar 

  66. Barenholz, Y. Doxil®—the first FDA-approved nano-drug: Lessons learned. J. Control. Release 2012, 160, 117–134.

    CAS  Google Scholar 

  67. Numico, G.; Castiglione, F.; Granetto, C.; Garrone, O.; Mariani, G.; Di Costanzo, G.; La Ciura, P.; Gasco, M.; Ostellino, O.; Porcile, G. et al. Single-agent pegylated liposomal doxorubicin (Caelix®) in chemotherapy pretreated non-small cell lung cancer patients: A pilot trial. Lung Cancer 2002, 35, 59–64.

    Google Scholar 

  68. Patlakas, G.; Bouros, D.; Tsantekidou-Pozova, S.; Koukourakis, M. I. Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer. Anticancer Res. 2005, 25, 1427–1431.

    CAS  Google Scholar 

  69. Leighl, N. B.; Goss, G. D.; Lopez, P. G.; Burkes, R. L.; Dancey, J. E.; Rahim, Y. H.; Rudinskas, L. C.; Pouliot, J. F.; Rodgers, A.; Pond, G. R. et al. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. Lung Cancer 2006, 52, 327–332.

    Google Scholar 

  70. Xu, C. N.; Wang, Y. B.; Guo, Z. P.; Chen, J.; Lin, L.; Wu, J. Y.; Tian, H. Y.; Chen, X. S. Pulmonary delivery by exploiting doxorubicin and cisplatin co-loaded nanoparticles for metastatic lung cancer therapy. J. Control. Release 2019, 295, 153–163.

    CAS  Google Scholar 

  71. Hoch, U.; Staschen, C. M.; Johnson, R. K.; Eldon, M. A. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother. Pharm. 2014, 74, 1125–1137.

    CAS  Google Scholar 

  72. Jameson, G. S.; Hamm, J. T.; Weiss, G. J.; Alemany, C.; Anthony, S.; Basche, M.; Ramanathan, R. K.; Borad, M. J.; Tibes, R.; Cohn, A. et al. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin. Cancer Res. 2013, 19, 268–278.

    CAS  Google Scholar 

  73. Aggarwal, C.; Cohen, R. B.; Yu, E.; Hwang, W. T.; Bauml, J. M.; Alley, E.; Evans, T. L.; Langer, C. J. Etirinotecan pegol (NKTR-102) in third-line treatment of patients with metastatic or recurrent non-small-cell lung cancer: Results of a phase II study. Clin. Lung Cancer 2018, 19, 157–162.

    CAS  Google Scholar 

  74. Zhang, H. J. Onivyde for the therapy of multiple solid tumors. OncoTargets Ther. 2016, 9, 3001–3007.

    CAS  Google Scholar 

  75. Leonard, S.; Lee, H.; Klinz, S.; Paz, N.; Fitzgerald, J.; Hendriks, B. P1.07-006 Preclinical support for evaluation of irinotecan liposome injection (nal-IRI, MM-398) in small cell lung cancer: Topic: Drug treatment alone and in combination with radiotherapy. J. Thorac. Oncol. 2017, 12, S699.

    Google Scholar 

  76. Landesman-Milo, D.; Ramishetti, S.; Peer, D. Nanomedicine as an emerging platform for metastatic lung cancer therapy. Cancer Metastasis Rev. 2015, 34, 291–301.

    CAS  Google Scholar 

  77. Zhang, Y. F.; Huang, Y. X.; Li, S. Polymeric micelles: Nanocarriers for cancer-targeted drug delivery. AAPS PharmSciTech. 2014, 15, 862–871.

    CAS  Google Scholar 

  78. Gupta, N.; Hatoum, H.; Dy, G. K. First line treatment of advanced non-small-cell lung cancer-specific focus on albumin bound paclitaxel. Int. J. Nanomedicine 2014, 9, 209–221.

    CAS  Google Scholar 

  79. Pazdur, R. J. N. C. I. a. t. N. I. o. H. R. A. FDA approval for paclitaxel albumin-stabilized nanoparticle formulation. National Cancer Institute at the National Institutes of Health 2012, 24, 2013.

    Google Scholar 

  80. Jiménez-López, J.; El-Hammadi, M. M.; Ortiz, R.; Cayero-Otero, M. D.; Cabeza, L.; Perazzoli, G.; Martin-Banderas, L.; Baeyens, J. M.; Prados, J.; Melguizo, C. A novel nanoformulation of PLGA with high non-ionic surfactant content improves in vitro and in vivo PTX activity against lung cancer. Pharmacol. Res. 2019, 141, 451–465.

    Google Scholar 

  81. Yang, Y.; Huang, Z. W.; Li, J. Y.; Mo, Z. R.; Huang, Y.; Ma, C.; Wang, W. H.; Pan, X.; Wu, C. B. PLGA porous microspheres dry powders for codelivery of afatinib-loaded solid lipid nanoparticles and paclitaxel: Novel therapy for EGFR tyrosine kinase inhibitors resistant nonsmall cell lung cancer. Adv. Healthc. Mater. 2019, 8, 1900965.

    CAS  Google Scholar 

  82. Ormerod, M. G.; Orr, R. M.; Peacock, J. H. The role of apoptosis in cell killing by cisplatin: A flow cytometric study. Br. J. Cancer 1994, 69, 93–100.

    CAS  Google Scholar 

  83. Sears, C. R.; Cooney, S. A.; Chin-Sinex, H.; Mendonca, M. S.; Turchi, J. J. DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer. DNA Rep. 2016, 40, 35–46.

    CAS  Google Scholar 

  84. Sun, M.; He, L.; Fan, Z.; Tang, R. P.; Du, J. Z. Effective treatment of drug-resistant lung cancer via a nanogel capable of reactivating cisplatin and enhancing early apoptosis. Biomaterials 2020, 257, 120252.

    CAS  Google Scholar 

  85. Iyer, R.; Nguyen, T.; Padanilam, D.; Xu, C. C.; Saha, D.; Nguyen, K. T.; Hong, Y. Glutathione-responsive biodegradable polyurethane nanoparticles for lung cancer treatment. J. Control. Release 2020, 321, 363–371.

    CAS  Google Scholar 

  86. Stathopoulos, G. P.; Boulikas, T. Lipoplatin formulation review article. J. Drug Deliv. 2012, 2012, 581363.

    CAS  Google Scholar 

  87. Kaltsas, K.; Anevlavis, S.; Pataka, A.; Kouliatsis, G.; Pozova, S.; Bouros, D.; Froudarakis, M. A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy. Eur. Respir. Soc. 2016, 48, OA3344.

    Google Scholar 

  88. Chan, M. H.; Huang, W. T.; Wang, J.; Liu, R. S.; Hsiao, M. Next-generation cancer-specific hybrid theranostic nanomaterials: MAGE-A3 NIR persistent luminescence nanoparticles conjugated to afatinib for in situ suppression of lung adenocarcinoma growth and metastasis. Adv. Sci. 2020, 7, 1903741.

    CAS  Google Scholar 

  89. Fehrenbacher, L.; Spira, A.; Ballinger, M.; Kowanetz, M.; Vansteenkiste, J.; Mazieres, J.; Park, K.; Smith, D.; Artal-Cortes, A.; Lewanski, C. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016, 387, 1837–1846.

    CAS  Google Scholar 

  90. Garon, E. B.; Rizvi, N. A.; Hui, R. N.; Leighl, N.; Balmanoukian, A. S.; Eder, J. P.; Patnaik, A.; Aggarwal, C.; Gubens, M.; Horn, L. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015, 372, 2018–2028.

    Google Scholar 

  91. Liu, B.; Cao, W.; Qiao, G. L.; Yao, S. Y.; Pan, S. J.; Wang, L. R.; Yue, C. X.; Ma, L. J.; Liu, Y. L.; Cui, D. X. Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer. Acta Biomater. 2019, 99, 307–319.

    CAS  Google Scholar 

  92. Duman, F. D.; Akkoc, Y.; Demirci, G.; Bavili, N.; Kiraz, A.; Gozuacik, D.; Acar, H. Y. Bypassing pro-survival and resistance mechanisms of autophagy in EGFR-positive lung cancer cells by targeted delivery of 5FU using theranostic Ag2S quantum dots. J. Mater. Chem. B. 2019, 7, 7363–7376.

    CAS  Google Scholar 

  93. Reda, M.; Ngamcherdtrakul, W.; Gu, S. D.; Bejan, D. S.; Siriwon, N.; Gray, J. W.; Yantasee, W. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer. Cancer Lett. 2019, 467, 9–18.

    CAS  Google Scholar 

  94. Bregoli, L.; Movia, D.; Gavigan-Imedio, J. D.; Lysaght, J.; Reynolds, J.; Prina-Mello, A. Nanomedicine applied to translational oncology: A future perspective on cancer treatment. Nanomedicine 2016, 12, 81–103.

    CAS  Google Scholar 

  95. Seidi, K.; Neubauer, H. A.; Moriggl, R.; Jahanban-Esfahlan, R.; Javaheri, T. Tumor target amplification: Implications for nano drug delivery systems. J. Control. Release 2018, 275, 142–161.

    CAS  Google Scholar 

  96. Chang, S. S.; O’Keefe, D. S.; Bacich, D. J.; Reuter, V. E.; Heston, W. D. W.; Gaudin, P. B. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Cancer Res. 1999, 5, 2674–2681.

    CAS  Google Scholar 

  97. Hrkach, J.; Von Hoff, D.; Mukkaram Ali, M.; Andrianova, E.; Auer, J.; Campbell, T.; De Witt, D.; Figa, M.; Figueiredo, M.; Horhota, A. et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 2012, 4, 128ra39.

    Google Scholar 

  98. Von Hoff, D. D.; Mita, M. M.; Ramanathan, R. K.; Weiss, G. J.; Mita, A. C.; LoRusso, P. M.; Burris III, H. A.; Hart, L. L.; Low, S. C.; Parsons, D. M. et al. Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clin. Cancer Res. 2016, 22, 3157–3163.

    CAS  Google Scholar 

  99. Viteri, S.; Rosell, R. An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs). Transl. Lung Cancer Res. 2018, 7, S1–S4.

    CAS  Google Scholar 

  100. Reid, G.; Kao, S. C.; Pavlakis, N.; Brahmbhatt, H.; MacDiarmid, J.; Clarke, S.; Boyer, M.; van Zandwijk, N. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. Epigenomics 2016, 8, 1079–1085.

    CAS  Google Scholar 

  101. Kao, S. C.; Fulham, M.; Wong, K.; Cooper, W.; Brahmbhatt, H.; MacDiarmid, J.; Pattison, S.; Sagong, J. O.; Huynh, Y.; Leslie, F. et al. A significant metabolic and radiological response after a novel targeted MicroRNA-based treatment approach in malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 2015, 191, 1467–1469.

    Google Scholar 

  102. Moro, M.; Di Paolo, D.; Milione, M.; Centonze, G.; Bornaghi, V.; Borzi, C.; Gandellini, P.; Perri, P.; Pastorino, U.; Ponzoni, M. et al. Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models. J. Control. Release 2019, 308, 44–56.

    CAS  Google Scholar 

  103. Lu, C.; Stewart, D. J.; Lee, J. J.; Ji, L.; Ramesh, R.; Jayachandran, G.; Nunez, M. I.; Wistuba, I. I.; Erasmus, J. J.; Hicks, M. E. et al. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One 2012, 7, e34833.

    CAS  Google Scholar 

  104. Sharma, S.; Srivastava, M. K.; Harris-White, M.; Lee, J. M.; Dubinett, S. MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancer. Expert Opin. Biol. Ther. 2011, 11, 987–990.

    CAS  Google Scholar 

  105. Butts, C.; Murray, N.; Maksymiuk, A.; Goss, G.; Marshall, E.; Soulières, D.; Cormier, Y.; Ellis, P.; Price, A.; Sawhney, R. et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 2005, 23, 6674–6681.

    CAS  Google Scholar 

  106. Wu, Y. L.; Park, K.; Soo, R. A.; Sun, Y.; Tyroller, K.; Wages, D.; Ely, G.; Yang, J. C. H.; Mok, T. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 2011, 11, 430.

    CAS  Google Scholar 

  107. Griesenbach, U.; Pytel, K. M.; Alton, E. W. F. W. Cystic fibrosis gene therapy in the UK and elsewhere. Hum. Gene Ther. 2015, 26, 266–275.

    CAS  Google Scholar 

  108. Hardee, C. L.; Arévalo-Soliz, L. M.; Hornstein, B. D.; Zechiedrich, L. Advances in non-viral DNA vectors for gene therapy. Genes 2017, 8, 65.

    Google Scholar 

  109. Konstan, M. W.; Davis, P. B.; Wagener, J. S.; Hilliard, K. A.; Stern, R. C.; Milgram, L. J. H.; Kowalczyk, T. H.; Hyatt, S. L.; Fink, T. L.; Gedeon, C. R. et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum. Gene Ther. 2004, 15, 1255–1269.

    CAS  Google Scholar 

  110. McLachlan, G.; Davidson, H.; Holder, E.; Davies, L. A.; Pringle, I. A.; Sumner-Jones, S. G.; Baker, A.; Tennant, P.; Gordon, C.; Vrettou, C. et al. Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung. Gene Ther. 2011, 18, 996–1005.

    CAS  Google Scholar 

  111. Alton, E. W. F. W.; Boyd, A. C.; Cheng, S. H.; Davies, J. C.; Davies, L. A.; Dayan, A.; Gill, D. R.; Griesenbach, U.; Higgins, T.; Hyde, S. C. et al. Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung. Gene Ther. 2014, 21, 89–95.

    CAS  Google Scholar 

  112. Alton, E. W. F. W.; Baker, A.; Baker, E.; Boyd, A. C.; Cheng, S. H.; Coles, R. L.; Collie, D. D. S.; Davidson, H.; Davies, J. C.; Gill, D. R. et al. The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep. Biomaterials 2013, 34, 10267–10277.

    CAS  Google Scholar 

  113. Alton, E. W. F. W.; Boyd, A. C.; Cheng, S. H.; Cunningham, S.; Davies, J. C.; Gill, D. R.; Griesenbach, U.; Higgins, T.; Hyde, S. C.; Innes, J. A. et al. A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis. Thorax 2013, 68, 1075–1077.

    Google Scholar 

  114. Alton, E. W. F. W.; Armstrong, D. K.; Ashby, D.; Bayfield, K. J.; Bilton, D.; Bloomfield, E. V.; Boyd, A. C.; Brand, J.; Buchan, R.; Calcedo, R. et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: A randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Res. Med. 2015, 3, 684–691.

    CAS  Google Scholar 

  115. Robinson, E.; MacDonald, K. D.; Slaughter, K.; McKinney, M.; Patel, S.; Sun, C.; Sahay, G. Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis. Mol. Ther. 2018, 26, 2034–2046.

    CAS  Google Scholar 

  116. Haque, A. K. M. A.; Dewerth, A.; Antony, J. S.; Riethmüller, J.; Schweizer, G. R.; Weinmann, P.; Latifi, N.; Yasar, H.; Pedemonte, N.; Sondo, E. et al. Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis. Sci. Rep. 2018, 8, 16776.

    Google Scholar 

  117. Tagalakis, A. D.; Munye, M. M.; Ivanova, R.; Chen, H. P.; Smith, C. M.; Aldossary, A. M.; Rosa, L. Z.; Moulding, D.; Barnes, J. L.; Kafetzis, K. N. et al. Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung. Thorax 2018, 73, 847–856.

    Google Scholar 

  118. Osman, G.; Rodriguez, J.; Chan, S. Y.; Chisholm, J.; Duncan, G.; Kim, N.; Tatler, A. L.; Shakesheff, K. M.; Hanes, J.; Suk, J. S. et al. PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy. J. Control. Release 2018, 285, 35–45.

    CAS  Google Scholar 

  119. Leal, J.; Peng, X. J.; Liu, X. Q.; Arasappan, D.; Wylie, D. C.; Schwartz, S. H.; Fullmer, J. J.; McWilliams, B. C.; Smyth, H. D. C.; Ghosh, D. Peptides as surface coatings of nanoparticles that penetrate human cystic fibrosis sputum and uniformly distribute in vivo following pulmonary delivery. J. Control. Release 2020, 322, 457–469.

    CAS  Google Scholar 

  120. Garbuzenko, O. B.; Kbah, N.; Kuzmov, A.; Pogrebnyak, N.; Pozharov, V.; Minko, T. Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers. J. Control. Release 2019, 296, 225–231.

    CAS  Google Scholar 

  121. Paranjpe, M.; Müller-Goymann, C. C. Nanoparticle-mediated pulmonary drug delivery: A review. Int. J. Mol. Sci. 2014, 15, 5852–5873.

    CAS  Google Scholar 

  122. Moreno-Sastre, M.; Pastor, M.; Salomon, C. J.; Esquisabel, A.; Pedraz, J. L. Pulmonary drug delivery: A review on nanocarriers for antibacterial chemotherapy. J. Antimicrob. Chemother. 2015, 70, 2945–2955.

    CAS  Google Scholar 

  123. Günday Türeli, N.; Torge, A.; Juntke, J.; Schwarz, B. C.; Schneider-Daum, N.; Türeli, A. E.; Lehr, C. M.; Schneider, M. Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections. Eur. J. Pharm. Biopharm. 2017, 117, 363–371.

    Google Scholar 

  124. Ernst, J.; Klinger-Strobel, M.; Arnold, K.; Thamm, J.; Hartung, A.; Pletz, M. W.; Makarewicz, O.; Fischer, D. Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions. Eur. J. Pharm. Biopharm. 2018, 131, 120–129.

    CAS  Google Scholar 

  125. Mirza, S.; Clay, R. D.; Koslow, M. A.; Scanlon, P. D. COPD guidelines: A Review of the 2018 GOLD Report. Mayo Clin. Proc. 2018, 93, 1488–1502.

    Google Scholar 

  126. da Silva, A. L.; Cruz, F. F.; Rocco, P. R. M.; Morales, M. M. New perspectives in nanotherapeutics for chronic respiratory diseases. Biophys. Rev. 2017, 9, 793–803.

    Google Scholar 

  127. Wu, L.; Shan, W.; Zhang, Z. R.; Huang, Y. Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties. Adv. Drug Deliv. Rev. 2018, 124, 150–163.

    CAS  Google Scholar 

  128. Ramos, F. L.; Krahnke, J. S.; Kim, V. Clinical issues of mucus accumulation in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2014, 9, 139–150.

    Google Scholar 

  129. Zhang, X.; Zhang, W. T.; Liu, L. Z.; Yang, M.; Huang, L. J.; Chen, K.; Wang, R.; Yang, B. W.; Zhang, D. D.; Wang, J. L. Antibiotic-loaded MoS2 nanosheets to combat bacterial resistance via biofilm inhibition. Nanotechnology 2017, 28, 225101.

    Google Scholar 

  130. Dua, K.; Shukla, S. D.; Tekade, R. K.; Hansbro, P. M. Whether a novel drug delivery system can overcome the problem of biofilms in respiratory diseases? Drug Deliv. Transl. Res. 2017, 7, 179–187.

    CAS  Google Scholar 

  131. Dua, K.; de Jesus Andreoli Pinto, T.; Chellappan, D. K.; Gupta, G.; Bebawy, M.; Hansbro, P. M. Advancements in nano drug delivery systems: A challenge for biofilms in respiratory diseases. Panminerva Med. 2018, 60, 35–36.

    Google Scholar 

  132. Mamary, A. J.; Criner, G. J. Tiotropium bromide for chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 2009, 3, 211–220.

    CAS  Google Scholar 

  133. Quon, B. S.; Goss, C. H.; Ramsey, B. W. Inhaled antibiotics for lower airway infections. Ann. Am. Thorac. Soc. 2014, 11, 425–434.

    CAS  Google Scholar 

  134. Varshosaz, J.; Ghaffari, S.; Mirshojaei, S. F.; Jafarian, A.; Atyabi, F.; Kobarfard, F.; Azarmi, S. Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery. BioMed Res. Int. 2013, 2013, 136859.

    CAS  Google Scholar 

  135. Kato, H.; Hagihara, M.; Hirai, J.; Sakanashi, D.; Suematsu, H.; Nishiyama, N.; Koizumi, Y.; Yamagishi, Y.; Matsuura, K.; Mikamo, H. Evaluation of amikacin pharmacokinetics and pharmacodynamics for optimal initial dosing regimen. Drugs R&D 2017, 17, 177–187.

    CAS  Google Scholar 

  136. Li, Z. B.; Luo, G. H.; Hu, W. P.; Hua, J. L.; Geng, S. Y.; Chu, P. K.; Zhang, J.; Wang, H. Y.; Yu, X. F. Mediated drug release from nanovehicles by black phosphorus quantum dots for efficient therapy of chronic obstructive pulmonary disease. Angew. Chem., Int. Ed. 2020, doi: https://doi.org/10.1002/anie.202008379.

  137. Chikuma, K.; Arima, K.; Asaba, Y.; Kubota, R.; Asayama, S.; Sato, K.; Kawakami, H. The potential of lipid-polymer nanoparticles as epigenetic and ROS control approaches for COPD. Free Radical Res. 2019, doi: https://doi.org/10.1080/10715762.2019.1696965.

  138. Mohamed, A.; Kunda, N. K.; Ross, K.; Hutcheon, G. A.; Saleem, I. Y. Polymeric nanoparticles for the delivery of miRNA to treat chronic obstructive pulmonary disease (COPD). Eur. J. Pharm. Biopharm. 2019, 136, 1–8.

    CAS  Google Scholar 

  139. Vij, N.; Min, T.; Marasigan, R.; Belcher, C. N.; Mazur, S.; Ding, H.; Yong, K. T.; Roy, I. Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J. Nanobiotechnol. 2010, 8, 22.

    Google Scholar 

  140. Roy, I.; Vij, N. Nanodelivery in airway diseases: Challenges and therapeutic applications. Nanomedicine 2010, 6, 237–244.

    CAS  Google Scholar 

  141. Vij, N. Nano-based theranostics for chronic obstructive lung diseases: Challenges and therapeutic potential. Expert. Opin. Drug Deliv. 2011, 8, 1105–1109.

    CAS  Google Scholar 

  142. Vij, N.; Min, T.; Bodas, M.; Gorde, A.; Roy, I. Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseases. Nanomedicine 2016, 12, 2415–2427.

    CAS  Google Scholar 

  143. Barnes, P. J.; Burney, P. G. J.; Silverman, E. K.; Celli, B. R.; Vestbo, J.; Wedzicha, J. A.; Wouters, E. F. Chronic obstructive pulmonary disease. Nat. Rev. Dis. Primers 2015, 1, 15076.

    Google Scholar 

  144. Andreeva, E.; Pokhaznikova, M.; Lebedev, A.; Moiseeva, I.; Kuznetsova, O.; Degryse, J. M. Spirometry is not enough to diagnose COPD in epidemiological studies: A follow-up study. Npj Prim. Care Respir. Med. 2017, 27, 62.

    Google Scholar 

  145. Fens, N.; Zwinderman, A. H.; van der Schee, M. P.; de Nijs, S. B.; Dijkers, E.; Roldaan, A. C.; Cheung, D.; Bel, E. H.; Sterk, P. J. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am. J. Respir. Crit. Care Med. 2009, 180, 1076–1082.

    CAS  Google Scholar 

  146. Dragonieri, S.; Annema, J. T.; Schot, R.; van der Schee, M. P. C.; Spanevello, A.; Carratú, P.; Resta, O.; Rabe, K. F.; Sterk, P. J. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer 2009, 64, 166–170.

    Google Scholar 

  147. Sibila, O.; Garcia-Bellmunt, L.; Giner, J.; Merino, J. L.; Suarez-Cuartin, G.; Torrego, A.; Solanes, I.; Castillo, D.; Valera, J. L.; Cosio, B. G. et al. Identification of airway bacterial colonization by an electronic nose in chronic obstructive pulmonary disease. Respir. Med. 2014, 108, 1608–1614.

    Google Scholar 

  148. Anusha, S.; CP, B.; Mohan, C. D.; Mathai, J.; Rangappa, S.; Mohan, S.; Chandra; Paricharak, S.; Mervin, L.; Fuchs, J. E. et al. A nano-MgO and ionic liquid-catalyzed ‘green’ synthesis protocol for the development of adamantyl-imidazolo-thiadiazoles as anti-tuberculosis agents targeting sterol 14α-demethylase (CYP51). PLoS One 2015, 10, e0139798.

    Google Scholar 

  149. Sharma, R.; Kaur, A.; Sharma, A. K.; Dilbaghi, N.; Sharma, A. K. Nano-based anti-tubercular drug delivery and therapeutic interventions in tuberculosis. Curr. Drug Targets 2017, 18, 72–86.

    CAS  Google Scholar 

  150. Nasiruddin, M.; Neyaz, M. K.; Das, S. Nanotechnology-based approach in tuberculosis treatment. Tuberc. Res Treat. 2017, 2017, 4920209.

    Google Scholar 

  151. Shojaei, T. R.; Mohd Salleh, M. A.; Tabatabaei, M.; Ekrami, A.; Motallebi, R.; Rahmani-Cherati, T.; Hajalilou, A.; Jorfi, R. Development of sandwich-form biosensor to detect Mycobacterium tuberculosis complex in clinical sputum specimens. Braz. J. Infect. Dis. 2014, 18, 600–608.

    Google Scholar 

  152. Wang, S. Q.; Inci, F.; De Libero, G.; Singhal, A.; Demirci, U. Point-of-care assays for tuberculosis: Role of nanotechnology/microfluidics. Biotechnol. Adv. 2013, 31, 438–449.

    Google Scholar 

  153. Yang, H.; Qin, L. H.; Wang, Y. L.; Zhang, B. B.; Liu, Z. H.; Ma, H.; Lu, J. M.; Huang, X. C.; Shi, D. L.; Hu, Z. Y. Detection of Mycobacterium tuberculosis based on H37Rv binding peptides using surface functionalized magnetic microspheres coupled with quantum dots—a nano detection method for Mycobacterium tuberculosis. Int. J. Nanomed. 2015, 10, 77–88.

    Google Scholar 

  154. Cadena, A. M.; Fortune, S. M.; Flynn, J. A. L. Heterogeneity in tuberculosis. Nat. Rev. Immunol. 2017, 17, 691–702.

    CAS  Google Scholar 

  155. Ellis, T.; Chiappi, M.; García-Trenco, A.; Al-Ejji, M.; Sarkar, S.; Georgiou, T. K.; Shaffer, M. S. P.; Tetley, T. D.; Schwander, S.; Ryan, M. P. et al. Multimetallic microparticles increase the potency of rifampicin against intracellular Mycobacterium tuberculosis. ACS Nano 2018, 12, 5228–5240.

    CAS  Google Scholar 

  156. Hwang, A. A.; Lee, B. Y.; Clemens, D. L.; Dillon, B. J.; Zink, J. I.; Horwitz, M. A. pH-responsive isoniazid-loaded nanoparticles markedly improve tuberculosis treatment in Mice. Small 2015, 11, 5066–5078.

    CAS  Google Scholar 

  157. Machelart, A.; Salzano, G.; Li, X.; Demars, A.; Debrie, A. S.; Menendez-Miranda, M.; Pancani, E.; Jouny, S.; Hoffmann, E.; Deboosere, N. et al. Intrinsic antibacterial activity of nanoparticles made of β-cyclodextrins potentiates their effect as drug nanocarriers against tuberculosis. ACS Nano 2019, 13, 3992–4007.

    CAS  Google Scholar 

  158. Pi, J.; Shen, L.; Yang, E. Z.; Shen, H. B.; Huang, D.; Wang, R.; Hu, C. M.; Jin, H.; Cai, H. H.; Cai, J. Y. et al. Macrophage-targeted isoniazid-selenium nanoparticles promote antimicrobial immunity and synergize bactericidal destruction of tuberculosis bacilli. Angew. Chem., Int. Ed. 2020, 59, 3226–3234.

    CAS  Google Scholar 

  159. Welin, A.; Björnsdottir, H.; Winther, M.; Christenson, K.; Oprea, T.; Karlsson, A.; Forsman, H.; Dahlgren, C.; Bylund, J. CFP-10 from Mycobacterium tuberculosis selectively activates human neutrophils through a pertussis toxin-sensitive chemotactic receptor. Infect. Immun. 2015, 83, 205–213.

    Google Scholar 

  160. Feng, T. T.; Shou, C. M.; Shen, L.; Qian, Y.; Wu, Z. G.; Fan, J.; Zhang, Y. Z.; Tang, Y. W.; Wu, N. P.; Lu, H. Z. et al. Novel monoclonal antibodies to ESAT-6 and CFP-10 antigens for ELISA-based diagnosis of pleural tuberculosis. Int. J. Tuberc. Lung Dis. 2011, 15, 804–810.

    Google Scholar 

  161. Liu, C.; Lyon, C. J.; Bu, Y.; Deng, Z. A.; Walters, E.; Li, Y.; Zhang, L. Q.; Hesseling, A. C.; Graviss, E. A.; Hu, Y. Clinical evaluation of a blood assay to diagnose paucibacillary tuberculosis via bacterial antigens. Clin. Chem. 2018, 64, 791–800.

    Google Scholar 

  162. Liu, C.; Zhao, Z.; Fan, J.; Lyon, C. J.; Wu, H. J.; Nedelkov, D.; Zelazny, A. M.; Olivier, K. N.; Cazares, L. H.; Holland, S. M. et al. Quantification of circulating Mycobacterium tuberculosis antigen peptides allows rapid diagnosis of active disease and treatment monitoring. Prac. Natl. Acad. Sci. USA 2017, 114, 3969–3974.

    CAS  Google Scholar 

  163. Phan, L. M. T.; Rafique, R.; Baek, S. H.; Nguyen, T. P.; Park, K. Y.; Kim, E. B.; Kim, J. G.; Park, J. P.; Kailasa, S. K.; Kim, H. J. et al. Gold-copper nanoshell dot-blot immunoassay for naked-eye sensitive detection of tuberculosis specific CFP-10 antigen. Biosens. Bioelectron. 2018, 121, 111–117.

    CAS  Google Scholar 

  164. Meers, P.; Neville, M.; Malinin, V.; Scotto, A. W.; Sardaryan, G.; Kurumunda, R.; Mackinson, C.; James, G.; Fisher, S.; Perkins, W. R. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J. Antimicrob. Chemother. 2008, 61, 859–868.

    CAS  Google Scholar 

  165. Ehsan, Z.; Clancy, J. P. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. Future Microbiol. 2015, 10, 1901–1912.

    CAS  Google Scholar 

  166. Waters, V.; Ratjen, F. Inhaled liposomal amikacin. Expert Rev. Respir. Med. 2014, 8, 401–409.

    CAS  Google Scholar 

  167. Costa-Gouveia, J.; Pancani, E.; Jouny, S.; Machelart, A.; Delorme, V.; Salzano, G.; Iantomasi, R.; Piveteau, C.; Queval, C. J.; Song, O. R. et al. Combination therapy for tuberculosis treatment: Pulmonary administration of ethionamide and booster co-loaded nanoparticles. Sci. Rep. 2017, 7, 5390.

    Google Scholar 

  168. Serisier, D. J.; Bilton, D.; De Soyza, A.; Thompson, P. J.; Kolbe, J.; Greville, H. W.; Cipolla, D.; Bruinenberg, P.; Gonda, I. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): A randomised, double-blind, placebo-controlled trial. Thorax 2013, 68, 812–817.

    Google Scholar 

  169. Doroudian, M.; MacLoughlin, R.; Poynton, F.; Prina-Mello, A.; Donnelly, S. C. Nanotechnology based therapeutics for lung disease. Thorax 2019, 74, 965–976.

    Google Scholar 

  170. Hamblin, K. A.; Wong, J. P.; Blanchard, J. D.; Atkins, H. S. The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy. Front. Cell. Infect. Microbiol. 2014, 4, 79.

    Google Scholar 

  171. Wong, J. P.; Yang, H. M.; Blasetti, K. L.; Schnell, G.; Conley, J.; Schofield, L. N. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control. Release 2003, 92, 265–273.

    CAS  Google Scholar 

  172. Haworth, C.; Wanner, A.; Froehlich, J.; O’Neal, T.; Davis, A.; Gonda, I.; O’Donnell, A. Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection: Results from two parallel phase III trials (ORBIT-3 and-4). Am. J. Respir. Crit. Care Med. 2017, 195, A7604

    Google Scholar 

  173. Ho, D. K.; Murgia, X.; De Rossi, C.; Christmann, R.; Hüfner de Mello Martins, A. G.; Koch, M.; Andreas, A.; Herrmann, J.; Müller, R.; Empting, M. et al. Squalenyl hydrogen sulfate nanoparticles for simultaneous delivery of tobramycin and an alkylquinolone quorum sensing inhibitor enable the eradication of P. aeruginosa biofilm infections. Angew. Chem., Int. Ed. 2020, 59, 10292–10296.

    CAS  Google Scholar 

  174. Gao, Y. F.; Wang, J.; Chai, M. Y.; Li, X.; Deng, Y. Y.; Jin, Q.; Ji, J. Size and charge adaptive clustered nanoparticles targeting the biofilm microenvironment for chronic lung infection management. ACS Nano 2020, 14, 5686–5699.

    CAS  Google Scholar 

  175. Wang, Y.; Yuan, Q.; Feng, W.; Pu, W. D.; Ding, J.; Zhang, H. J.; Li, X. Y.; Yang, B.; Dai, Q.; Cheng, L. et al. Targeted delivery of antibiotics to the infected pulmonary tissues using ROS-responsive nanoparticles. J. Nanobiotechnol. 2019, 17, 103.

    Google Scholar 

  176. Zhang, C. Y.; Lin, W. J.; Gao, J.; Shi, X. T.; Davaritouchaee, M.; Nielsen, A. E.; Mancini, R. J.; Wang, Z. J. pH-responsive nanoparticles targeted to lungs for improved therapy of acute lung inflammation/injury. ACS Appl. Mater. Interfaces 2019, 11, 16380–16390.

    CAS  Google Scholar 

  177. Shirkhani, K.; Teo, I.; Armstrong-James, D.; Shaunak, S. Nebulised amphotericin B-polymethacrylic acid nanoparticle prophylaxis prevents invasive aspergillosis. Nanomedicine 2015, 11, 1217–1226.

    CAS  Google Scholar 

  178. Tang, Y. X.; Wu, S.; Lin, J. Q.; Cheng, L. T.; Zhou, J.; Xie, J.; Huang, K. X.; Wang, X. Y.; Yu, Y.; Chen, Z. B. et al. Nanoparticles targeted against cryptococcal pneumonia by interactions between chitosan and its peptide ligand. Nano Lett. 2018, 18, 6207–6213.

    CAS  Google Scholar 

  179. Qiu, L. X.; Hu, B. C.; Chen, H. B.; Li, S. S.; Hu, Y. Q.; Zheng, Y.; Wu, X. X. Antifungal efficacy of itraconazole-loaded TPGS-b-(PCL-ran-PGA) nanoparticles. Int. J. Nanomedicine 2015, 10, 1415–1423.

    CAS  Google Scholar 

  180. Wang, J.; Li, P. Y.; Yu, Y.; Fu, Y. H.; Jiang, H. Y.; Lu, M.; Sun, Z. P.; Jiang, S. B.; Lu, L.; Wu, M. X. Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science 2020, 367, eaau0810.

    CAS  Google Scholar 

  181. Sanchez-Guzman, D.; Le Guen, P.; Villeret, B.; Sola, N.; Le Borgne, R.; Guyard, A.; Kemmel, A.; Crestani, B.; Sallenave, J. M.; Garcia-Verdugo, I. Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgA-mediated mucosal immunity. Biomaterials 2019, 217, 119308.

    CAS  Google Scholar 

  182. Kim, H.; Park, M.; Hwang, J.; Kim, J. H.; Chung, D. R.; Lee, K. S.; Kang, M. Development of label-free colorimetric assay for MERS-CoV using gold nanoparticles. ACS Sens. 2019, 4, 1306–1312.

    CAS  Google Scholar 

  183. Layqah, L. A.; Eissa, S. An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes. Microchim. Acta 2019, 186, 224.

    Google Scholar 

  184. Holgate, S. T.; Wenzel, S.; Postma, D. S.; Weiss, S. T.; Renz, H.; Sly, P. D. Asthma. Nat. Rev. Dis. Primers 2015, 1, 15025.

    Google Scholar 

  185. Huang, C. L.; Wang, Y. M.; Li, X. W.; Ren, L. L.; Zhao, J. P.; Hu, Y.; Zhang, L.; Fan, G. H.; Xu, J. Y.; Gu, X. Y. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506.

    CAS  Google Scholar 

  186. Wang, D. W.; Hu, B.; Hu, C.; Zhu, F. F.; Liu, X.; Zhang, J.; Wang, B. B.; Xiang, H.; Cheng, Z. S.; Xiong, Y. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020, 323, 1061–1069.

    CAS  Google Scholar 

  187. Zhou, P.; Yang, X. L.; Wang, X. G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H. R.; Zhu, Y.; Li, B.; Huang, C. L. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020, 579, 270–273.

    CAS  Google Scholar 

  188. Zhu, N.; Zhang, D. Y.; Wang, W. L.; Li, X. W.; Yang, B.; Song, J. D.; Zhao, X.; Huang, B. Y.; Shi, W. F.; Lu, R. J. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727–733.

    CAS  Google Scholar 

  189. Wu, F.; Zhao, S.; Yu, B.; Chen, Y. M.; Wang, W.; Song, Z. G.; Hu, Y.; Tao, Z. W.; Tian, J. H.; Pei, Y. Y. et al. A new coronavirus associated with human respiratory disease in China. Nature 2020, 579, 265–269.

    CAS  Google Scholar 

  190. Udugama, B.; Kadhiresan, P.; Kozlowski, H. N.; Malekjahani, A.; Osborne, M.; Li, V. Y. C.; Chen, H. M.; Mubareka, S.; Gubbay, J. B.; Chan, W. C. W. Diagnosing COVID-19: The disease and tools for detection. ACS nano. 2020, 14, 3822–3835.

    CAS  Google Scholar 

  191. Moitra, P.; Alafeef, M.; Dighe, K.; Frieman, M. B.; Pan, D. Selective naked-eye detection of SARS-CoV-2 mediated by n gene targeted antisense oligonucleotide capped plasmonic nanoparticles. ACS Nano 2020, 14, 7617–7627.

    CAS  Google Scholar 

  192. Chen, Z. H.; Zhang, Z. G.; Zhai, X. M.; Li, Y. Y.; Lin, L.; Zhao, H.; Bian, L.; Li, P.; Yu, L.; Wu, Y. S. et al. Rapid and sensitive detection of anti-SARS-CoV-2 IgG, using lanthanide-doped nanoparticles-based lateral flow immunoassay. Anal. Chem. 2020, 92, 7226–7231.

    CAS  Google Scholar 

  193. Yadavalli, T.; Shukla, D. Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections. Nanomedicine 2017, 13, 219–230.

    CAS  Google Scholar 

  194. Quesada-González, D.; Merkoçi, A. Nanomaterial-based devices for point-of-care diagnostic applications. Chem. Soc. Rev. 2018, 47, 4697–4709.

    Google Scholar 

  195. Maltez-da Costa, M.; de la Escosura-Muñiz, A.; Nogués, C.; Barrios, L.; Ibáñez, E.; Merkoçi, A. Simple monitoring of cancer cells using nanoparticles. Nano Lett. 2012, 12, 4164–4171.

    CAS  Google Scholar 

  196. Seo, G.; Lee, G.; Kim, M. J.; Baek, S. H.; Choi, M.; Ku, K. B.; Lee, C. S.; Jun, S.; Park, D.; Kim, H. G. et al. Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor. ACS Nano 2020, 14, 5135–5142.

    CAS  Google Scholar 

  197. Szunerits, S.; Barras, A.; Khanal, M.; Pagneux, Q.; Boukherroub, R. Nanostructures for the inhibition of viral infections. Molecules 2015, 20, 14051–14081.

    CAS  Google Scholar 

  198. Fahmi, M. Z.; Sukmayani, W.; Khairunisa, S. Q.; Witaningrum, A. M.; Indriati, D. W.; Matondang, M. Q. Y.; Chang, J. Y.; Kotaki, T.; Kameoka, M. Design of boronic acid-attributed carbon dots on inhibits HIV-1 entry. RSC Adv. 2016, 6, 92996–93002.

    CAS  Google Scholar 

  199. Łoczechin, A.; Séron, K.; Barras, A.; Giovanelli, E.; Belouzard, S.; Chen, Y. T.; Metzler-Nolte, N.; Boukherroub, R.; Dubuisson, J.; Szunerits, S. Functional carbon quantum dots as medical countermeasures to human coronavirus. ACS Appl. Mater. Interfaces 2019, 11, 42964–42974.

    Google Scholar 

  200. Yuan, Y.; Cao, D. F.; Zhang, Y. F.; Ma, J.; Qi, J. X.; Wang, Q. H.; Lu, G. W.; Wu, Y.; Yan, J. H.; Shi, Y. et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat. Commun. 2017, 8, 15092.

    CAS  Google Scholar 

  201. Raj, V. S.; Mou, H.; Smits, S. L.; Dekkers, D. H. W.; Müller, M. A.; Dijkman, R.; Muth, D.; Demmers, J. A. A.; Zaki, A.; Fouchier, R. A. M. et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013, 495, 251–254.

    CAS  Google Scholar 

  202. Coleman, C. M.; Venkataraman, T.; Liu, Y. V.; Glenn, G. M.; Smith, G. E.; Flyer, D. C.; Frieman, M. B. MERS-CoV spike nanoparticles protect mice from MERS-CoV infection. Vaccine 2017, 35, 1586–1589.

    CAS  Google Scholar 

  203. Shereen, M. A.; Khan, S.; Kazmi, A.; Bashir, N.; Siddique, R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J. Adv. Res. 2020, 24, 91–98.

    CAS  Google Scholar 

  204. Monteil, V.; Kwon, H.; Prado, P.; Hagelkrüys, A.; Wimmer, R. A.; Stahl, M.; Leopoldi, A.; Garreta, E.; Hurtado Del Pozo, C.; Prosper, F. et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020, 181, 905–913.e7.

    CAS  Google Scholar 

  205. Zhang, H. B.; Penninger, J. M.; Li, Y. M.; Zhong, N. S.; Slutsky, A. S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intens. Care Med. 2020, 46, 586–590.

    CAS  Google Scholar 

  206. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T. S.; Herrler, G.; Wu, N. H.; Nitsche, A. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020, 181, 271–280.e8.

    CAS  Google Scholar 

  207. Singh, L.; Kruger, H. G.; Maguire, G. E. M.; Govender, T.; Parboosing, R. The role of nanotechnology in the treatment of viral infections. Ther. Adv. Infect. Dis. 2017, 4, 105–131.

    CAS  Google Scholar 

  208. Jackman, J. A.; Lee, J.; Cho, N. J. Nanomedicine for infectious disease applications: Innovation towards broad-spectrum treatment of viral infections. Small 2016, 12, 1133–1139.

    CAS  Google Scholar 

  209. Adesina, S. K.; Akala, E. O. Nanotechnology approaches for the delivery of exogenous siRNA for HIV therapy. Mol. Pharmaceutics 2015, 12, 4175–4187.

    CAS  Google Scholar 

  210. Richardson, P.; Griffin, I.; Tucker, C.; Smith, D.; Oechsle, O.; Phelan, A.; Rawling, M.; Savory, E.; Stebbing, J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020, 395, e30–e31.

    CAS  Google Scholar 

  211. Pu, S. Y.; Xiao, F.; Schor, S.; Bekerman, E.; Zanini, F.; Barouch-Bentov, R.; Nagamine, C. M.; Einav, S. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antiviral. Res. 2018, 155, 67–75.

    CAS  Google Scholar 

  212. Chen, N. S.; Zhou, M.; Dong, X.; Qu, J. M.; Gong, F. Y.; Han, Y.; Qiu, Y.; Wang, J. L.; Liu, Y.; Wei, Y. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020, 395, 507–513.

    CAS  Google Scholar 

  213. Xu, H. P.; He, C. Y.; Liu, Y.; Jiang, J. L.; Ma, T. Novel therapeutic modalities and drug delivery-erlotinib liposomes modified with galactosylated lipid: In vitro and in vivo investigations. Artif. Cells Nanomed. Biotechnol. 2018, 46, 1902–1907.

    CAS  Google Scholar 

  214. Zeng, C. X.; Hou, X. C.; Yan, J. Y.; Zhang, C. X.; Li, W. Q.; Zhao, W. Y.; Du, S.; Dong, Y. Z. Leveraging mRNAs sequences to express SARS-CoV-2 antigens in vivo. bioRxiv 2020, doi: https://doi.org/10.1101/2020.04.01.019877.

  215. Broza, Y. Y.; Haick, H. Nanomaterial-based sensors for detection of disease by volatile organic compounds. Nanomedicine 2013, 8, 785–806.

    CAS  Google Scholar 

  216. Dragonieri, S.; Schot, R.; Mertens, B. J. A.; Le Cessie, S.; Gauw, S. A.; Spanevello, A.; Resta, O.; Willard, N. P.; Vink, T. J.; Rabe, K. F. et al. An electronic nose in the discrimination of patients with asthma and controls. J. Allergy Clin. Immunol. 2007, 120, 856–862.

    Google Scholar 

  217. Taylor, S. L.; Leong, L. E. X.; Choo, J. M.; Wesselingh, S.; Yang, I. A.; Upham, J. W.; Reynolds, P. N.; Hodge, S.; James, A. L.; Jenkins, C. et al. Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology. J. Allergy Clin. Immunol. 2018, 141, 94–103.e15.

    Google Scholar 

  218. Plaza, V.; Crespo, A.; Giner, J.; Merino, J. L.; Ramos-Barbón, D.; Mateus, E. F.; Torrego, A.; Cosio, B. G.; Agustí, A.; Sibila, O. Inflammatory asthma phenotype discrimination using an electronic nose breath analyzer. J. Investig. Allergol. Clin. Immunol. 2015, 25, 431–437.

    CAS  Google Scholar 

  219. Keil, T. W. M.; Feldmann, D. P.; Costabile, G.; Zhong, Q.; da Rocha, S.; Merkel, O. M. Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles. Eur. J. Pharm. Biopharm. 2019, 143, 61–69.

    CAS  Google Scholar 

  220. Bhavna; Ahmad, F. J.; Mittal, G.; Jain, G. K.; Malhotra, G.; Khar, R. K.; Bhatnagar, A. Nano-salbutamol dry powder inhalation: A new approach for treating broncho-constrictive conditions. Eur. J. Pharm. Biopharm. 2009, 71, 282–291.

    CAS  Google Scholar 

  221. Matsuo, Y.; Ishihara, T.; Ishizaki, J.; Miyamoto, K. I.; Higaki, M.; Yamashita, N. Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell. Immunol. 2009, 260, 33–38.

    CAS  Google Scholar 

  222. Nasr, M.; Najlah, M.; D’Emanuele, A.; Elhissi, A. PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization. Int. J. Pharmaceut. 2014, 461, 242–250.

    CAS  Google Scholar 

  223. Kenyon, N. J.; Bratt, J. M.; Lee, J.; Luo, J. T.; Franzi, L. M.; Zeki, A. A.; Lam, K. S. Self-assembling nanoparticles containing dexamethasone as a novel therapy in allergic airways inflammation. PLoS One 2013, 8, e77730.

    CAS  Google Scholar 

  224. Chen, X. Y.; Huang, W. H.; Wong, B. C.; Yin, L. L.; Wong, Y. F.; Xu, M.; Yang, Z. J. Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int. J. Nanomedicine 2012, 7, 1139–1148.

    CAS  Google Scholar 

  225. Arafa, M. G.; Ayoub, B. M. Nano-vesicles of salbutamol sulphate in metered dose inhalers: Formulation, characterization and in vitro evaluation. Int. J. Appl. Pharmaceut. 2017, 9, 100–105.

    CAS  Google Scholar 

  226. Wang, K.; Feng, Y. P.; Li, S.; Li, W. J.; Chen, X.; Yi, R.; Zhang, H. R.; Hong, Z. Y. Oral delivery of bavachinin-loaded PEG-PLGA nanoparticles for asthma treatment in a murine model. J. Biomed. Nanotechnol. 2018, 14, 1806–1815.

    CAS  Google Scholar 

  227. Chakraborty, S.; Ehsan, I.; Mukherjee, B.; Mondal, L.; Roy, S.; Saha, K. D.; Paul, B.; Debnath, M. C.; Bera, T. Therapeutic potential of andrographolide-loaded nanoparticles on a murine asthma model. Nanomedicine 2019, 20, 102006.

    CAS  Google Scholar 

  228. Joshi, V. B.; Adamcakova-Dodd, A.; Jing, X. F.; Wongrakpanich, A.; Gibson-Corley, K. N.; Thorne, P. S.; Salem, A. K. Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy. AAPS J. 2014, 16, 975–985.

    CAS  Google Scholar 

  229. Salem, A. K. A promising CpG adjuvant-loaded nanoparticle-based vaccine for treatment of dust mite allergies. Immunotherapy 2014, 6, 1161–1163.

    CAS  Google Scholar 

  230. Grozdanovic, M.; Laffey, K. G.; Abdelkarim, H.; Hitchinson, B.; Harijith, A.; Moon, H. G.; Park, G. Y.; Rousslang, L. K.; Masterson, J. C.; Furuta, G. T. et al. Novel peptide nanoparticle-biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness. J. Allergy Clin. Immunol. 2019, 143, 669–680. e612.

    CAS  Google Scholar 

  231. Kumar, M.; Kong, X. Y.; Behera, A. K.; Hellermann, G. R.; Lockey, R. F.; Mohapatra, S. S. Chitosan IFN- γ -pDNA nanoparticle (CIN) therapy for allergic asthma. Genet. Vaccines Ther. 2003, 1, 3.

    Google Scholar 

  232. Kong, X. Y.; Hellermann, G. R.; Zhang, W. D.; Jena, P.; Kumar, M.; Behera, A.; Behera, S.; Lockey, R.; Mohapatra, S. S. Chitosan interferon-γ nanogene therapy for lung disease: Modulation of T-cell and dendritic cell immune responses. Allergy Asthma Clin. Immnuol. 2008, 4, 95–105.

    CAS  Google Scholar 

  233. Farokhzad, O. C.; Langer, R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3, 16–20.

    CAS  Google Scholar 

  234. Shi, J. J.; Votruba, A. R.; Farokhzad, O. C.; Langer, R. Nanotechnology in drug delivery and tissue engineering: From discovery to applications. Nano Lett. 2010, 10, 3223–3230.

    CAS  Google Scholar 

  235. Sanhai, W. R.; Sakamoto, J. H.; Canady, R.; Ferrari, M. Seven challenges for nanomedicine. Nat. Nanotechnol. 2008, 3, 242–244.

    CAS  Google Scholar 

  236. Sanders, N.; Rudolph, C.; Braeckmans, K.; De Smedt, S. C.; Demeester, J. Extracellular barriers in respiratory gene therapy. Adv. Drug Deliv. Rev. 2009, 61, 115–127.

    CAS  Google Scholar 

  237. Lai, S. K.; Wang, Y. Y.; Hanes, J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 2009, 61, 158–171.

    CAS  Google Scholar 

  238. Lai, S. K.; Wang, Y. Y.; Wirtz, D.; Hanes, J. Micro- and macrorheology of mucus. Adv. Drug Deliv. Rev. 2009, 61, 86–100.

    CAS  Google Scholar 

  239. Petros, R. A.; DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010, 9, 615–627.

    CAS  Google Scholar 

  240. Dobrovolskaia, M. A.; McNeil, S. E. Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007, 2, 469–478.

    CAS  Google Scholar 

  241. Schuster, B. S.; Suk, J. S.; Woodworth, G. F.; Hanes, J. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials 2013, 34, 3439–3446.

    CAS  Google Scholar 

  242. Huckaby, J. T.; Lai, S. K. PEGylation for enhancing nanoparticle diffusion in mucus. Adv. Drug Deliv. Rev. 2018, 124, 125–139.

    CAS  Google Scholar 

  243. Shi, J. J.; Kantoff, P. W.; Wooster, R.; Farokhzad, O. C. Cancer nanomedicine: Progress, challenges and opportunities. Nat. Rev. Cancer 2017, 17, 20–37.

    CAS  Google Scholar 

  244. Hare, J. I.; Lammers, T.; Ashford, M. B.; Puri, S.; Storm, G.; Barry, S. T. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv. Drug Deliv. Rev. 2017, 108, 25–38.

    CAS  Google Scholar 

  245. Kuzmov, A.; Minko, T. Nanotechnology approaches for inhalation treatment of lung diseases. J. Control. Release 2015, 219, 500–518.

    CAS  Google Scholar 

  246. Hossen, S.; Hossain, M. K.; Basher, M. K.; Mia, M. N. H.; Rahman, M. T.; Uddin, M. J. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review. J. Adv. Res. 2019, 15, 1–18.

    CAS  Google Scholar 

  247. Wilhelm, S.; Tavares, A. J.; Dai, Q.; Ohta, S.; Audet, J.; Dvorak, H. F.; Chan, W. C. W. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 2016, 1, 16014.

    CAS  Google Scholar 

  248. Genchi, G. G.; Marino, A.; Tapeinos, C.; Ciofani, G. Smart materials meet multifunctional biomedical devices: Current and prospective implications for nanomedicine. Front. Bioeng. Biotechnol. 2017, 5, 80.

    Google Scholar 

Download references

Acknowledgements

This research was supported by the National Science and Technology Major Project of the Ministry of Science and Technology of China (No. 2018ZX10301402), the National Natural Science Foundation of China (No. 51973243), the International Cooperation and Exchange of the National Natural Science Foundation of China (No. 51820105004), the Guangdong Innovative and Entrepreneurial Research Team Program (No. 2016ZT06S029), the Guangdong Basic and Applied Basic Research Foundation (No. 2019A1515110903), the Sanming Project of Medicine in Shenzhen (No. SZSM201911004) and the Research Start-up Fund of Post-doctoral, of SAHSYSU (No. ZSQYRSFPD0016).

Author information

Author notes

  1. Wenhao Zhong and Xinyu Zhang contributed equally to this work.

Affiliations

  1. Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, China

    Wenhao Zhong, Xinyu Zhang, Yunxin Zeng, Dongjun Lin & Jun Wu

  2. Key Laboratory of Sensing Technology and Biomedical Instrument of Guangdong Province, School of Biomedical Engineering, Sun Yat-sen University, Guangzhou, 510006, China

    Jun Wu

Authors
  1. Wenhao Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinyu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yunxin Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dongjun Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jun Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Dongjun Lin or Jun Wu.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhong, W., Zhang, X., Zeng, Y. et al. Recent applications and strategies in nanotechnology for lung diseases. Nano Res. 14, 2067–2089 (2021). https://doi.org/10.1007/s12274-020-3180-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12274-020-3180-3

Keywords

  • lung diseases
  • drug delivery
  • nanoparticles